Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 11/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901220 | 0.83 | KMT2A (0.46) | PIN1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL30466223 | 0.82 | PIN1 (0.71) | PIN1ALDH1A1 | |
| SCHEMBL6012734 | 0.75 | OPRL1 (0.48) | MC4RGSK3AGSK3B | |
| SCHEMBL4868611 | 0.74 | PIN1 (0.34) | PIN1MAPK1ALDH1A1 | |
| SCHEMBL15478093 | 0.74 | HCRTR1 (0.51) | MC4RKDM4ETP53MAPTHPGD | |
| SCHEMBL4867845 | 0.73 | TSHR (0.45) | PIN1KDM4EMAPTMAPK1ALDH1A1 | |
| Simufilam SCHEMBL12627054 | 0.72 | MC4R (0.46) | MC4RGSK3AGSK3BKDM4ETP53 | |
| SCHEMBL5780475 | 0.72 | RAB9A (0.50) | MAPTHPGDALDH1A1MEN1KMT2A | |
| Simufilam SCHEMBL22361802 | 0.71 | MC4R (0.45) | MC4RGSK3AGSK3BKDM4ETP53 | |
| Simufilam SCHEMBL22361808 | 0.71 | MC4R (0.45) | MC4RGSK3AGSK3BKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | disclosed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | PIN1 886/4885MC4R 1860/4885GSK3A 400/4885 |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | PMP22, PYGB, GAP43 | PIN1 849/4885MC4R 2054/4885GSK3A 330/4885 |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | PMP22, PYGB, GAP43 | PIN1 886/4885MC4R 1860/4885GSK3A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.